Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Kien Thiam Tan"'
Autor:
Shang‐Hung Chen, Ka‐Po Tse, Yen‐Jung Lu, Shu‐Jen Chen, Yu‐Feng Tian, Kien Thiam Tan, Chien‐Feng Li
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Breast cancer is a heterogeneous disease categorized based on molecular characteristics, including hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression levels. The emergence of profiling technology
Externí odkaz:
https://doaj.org/article/556eec84f6ec4018be34d1e7a502c792
Autor:
Angel Chao, Shu-Jen Chen, Hua-Chien Chen, Kien Thiam Tan, Wen Hsiao, Shih-Ming Jung, Lan-Yan Yang, Kuan-Gen Huang, Hung-Hsueh Chou, Huei-Jean Huang, Ting-Chang Chang, An-Shine Chao, Yun-Hsien Lee, Ren-Chin Wu, Chyong-Huey Lai
Publikováno v:
Biomedical Journal, Vol 46, Iss 5, Pp 100563- (2023)
Background: We investigated whether mutations in plasma circulating tumor DNA (ctDNA) can provide prognostic insight in patients with different histological types of ovarian carcinoma. We also examined the concordance of mutations detected in ctDNA s
Externí odkaz:
https://doaj.org/article/3bcb0cd987684ff4b45d2cca18cdf02a
Autor:
Po-Han Lin, Ling-Ming Tseng, Yi-Hsuan Lee, Shou-Tung Chen, Dah-Cherng Yeh, Ming-Shen Dai, Liang-Chih Liu, Ming-Yang Wang, Chiao Lo, Stanley Chang, Kien Thiam Tan, Shu-Jen Chen, Sung-Hsin Kuo, Chiun-Sheng Huang
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 12, Pp 2538-2547 (2022)
Background: The prognosis of triple-negative breast cancer (TNBC) is worse and a major proportion of TNBC expresses epidermal growth factor receptor (EGFR). Afatinib can inhibit EGFR signal pathway; however, its treatment effect for TNBC is unknown.
Externí odkaz:
https://doaj.org/article/33e09497336746968e55f30da7ec0b96
Autor:
John Wen‐Cheng Chang, Chien‐Jung Huang, Wen‐Kuan Huang, Yu‐Chao Wang, Jia‐Juan Hsieh, Yao‐Yu Chang, Yen‐Lin Huang, Chia‐Ling Wu, Yeh‐Han Wang, Shu‐Jen Chen, Kien Thiam Tan, Chiao‐Ping Chen, Chiao‐En Wu
Publikováno v:
Clinical & Translational Immunology, Vol 12, Iss 8, Pp n/a-n/a (2023)
Abstract Objective Genomic biomarkers predicting immune checkpoint inhibitor (ICI) treatment outcomes for Asian metastatic melanoma have been rarely reported. This study presents data on next‐generation sequencing (NGS) and tumour microenvironment
Externí odkaz:
https://doaj.org/article/9d3e16d3182b40b6b8ab13363b85fb2d
Autor:
Nina Lapke, Chien-Hung Chen, Ting-Chang Chang, Angel Chao, Yen-Jung Lu, Chyong-Huey Lai, Kien Thiam Tan, Hua-Chien Chen, Hsiao-Yun Lu, Shu-Jen Chen
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background Genetic alterations for epithelial ovarian cancer are insufficiently characterized. Previous studies are limited regarding included histologies, gene numbers, copy number variant (CNV) detection, and interpretation of pathway alte
Externí odkaz:
https://doaj.org/article/264108415813470b91d938e7123435dd
Autor:
Shih-Chieh Chang, Yi-Chun Lai, Cheng-Yu Chang, Li-Kuo Huang, Shu-Jen Chen, Kien Thiam Tan, Pei-Ning Yu, Jiun-I Lai
Publikováno v:
Translational Oncology, Vol 12, Iss 11, Pp 1425-1431 (2019)
Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKI) are recommended first-line therapy for advanced non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations. It is of clinical interest to identify concurrent genetic muta
Externí odkaz:
https://doaj.org/article/e12293159a2a4252acfcd79f50fdab8c
Autor:
Shu-Jen Chen, Jen-Hao Cheng, Kien Thiam Tan, Chun-Nan Yeh, Yu-Chan Chang, Wen-Liang Fang, Yi-Chen Yeh, Yu-Chao Wang, Dennis Shin-Shian Hsu, Chiao-En Wu, Jiun-I Lai, Peter Mu-Hsin Chang, Ming-Han Chen, Meng-Lun Lu, Michael Hsiao, Ming-Huang Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundImmunological checkpoint blockade is effective in treating various malignancies. Identifying predictive biomarkers to assist patient selection for immunotherapy has become a priority in both clinical and research settings.MethodsMutations i
Externí odkaz:
https://doaj.org/article/567d2eae34a94afb93bcfff699a9195f
Publikováno v:
Case Reports in Oncological Medicine, Vol 2020 (2020)
For non-small-cell lung cancer (NSCLC) patients without established actionable alterations in genes such as EGFR or ALK, options for targeted therapy remain limited in clinical practice. About 5% of lung adenocarcinoma patients have tumors with ERBB2
Externí odkaz:
https://doaj.org/article/94693f7df57d4b7cba72864c3fd96216
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 5, p 357 (2021)
Primary pulmonary artery sarcoma (PPAS) is a rare malignancy arising from mesenchymal pulmonary artery cells and mimics pulmonary embolism. Palliative chemotherapy such as anthracycline- or ifosfamide-based regimens and targeted therapy are the only
Externí odkaz:
https://doaj.org/article/877b06eb9e5c4b3fa11bbf4938b49720
Autor:
Fiona Tsui-Fen Cheng, Nina Lapke, Chin-Chu Wu, Yen-Jung Lu, Shu-Jen Chen, Pei-Ning Yu, Yen-Ting Liu, Kien Thiam Tan
Publikováno v:
Case Reports in Oncological Medicine, Vol 2019 (2019)
Genetic alterations in circulating tumor DNA (ctDNA) are an emerging biomarker for the early detection of relapse and have the potential to guide targeted treatment. ctDNA analysis is often performed by droplet digital PCR; however, next-generation s
Externí odkaz:
https://doaj.org/article/9725e2f008fd426b9abc87c0900b2fba